The Mainz-based company Biontech continues to benefit greatly from the great demand for its corona vaccine. In the first half of the year, Biontech had sales of 9.6 billion euros and a profit of 5.4 billion euros, as the company announced on Monday.
For the year as a whole, Biontech is aiming for sales of between EUR 13 billion and EUR 17 billion.
Preparations for the market launch of two new vaccines adapted to new corona variants are “in full swing,” Biontech said. The delivery of the vaccines could begin “subject to official approvals” from October.
The “product pipeline” also includes next-generation vaccine candidates aimed at longer and broader protection against the virus, according to company boss and founder Ugur Sahin.
